P433: Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;D'Haens, G.(2);Seenan, J.P.(3);Caprioli, F.(4,5);Siegel, C.(6);Nakamura, M.(7);Wei, S.C.(8);Kligys, K.(9);Zhang, Y.(9);Zambrano, J.(9);Song, A.P.(9);Ferrante, M.(10);
(1)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;(2)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands Antilles;(3)Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom;(4)Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy;(5)Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico di Milano, Gastroenterology and Endoscopy Unit, Milan, Italy;(6)Dartmouth-Hitchcock Medical Center, Inflammatory Bowel Disease Center- Section of Gastroenterology and Hepatology, Lebanon, United States;(7)Nagoya University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Nagoya, Japan;(8)National Taiwan University Hospital and College of Medicine, Department of Internal Medicine, Taipei, Taiwan;(9)AbbVie Inc., Research and Development, North Chicago, United States;(10)KU Leuven, Department of Gastroenterology and Hepatology- University Hospitals Leuven, Leuven, Belgium;
P434: Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn's disease: Results from induction and maintenance phase 3 trialsECCO’23 CopenhagenYear: 2023
Authors: Ghosh, S.(1)*;Feagan, B.(2);Parra, R.S.(3);Lopes, S.(4);Steinlauf, A.(5);Kakuta, Y.(6);Joshi, N.(7);Lee, W.J.(7);Remple, V.(7);Lacerda, A.P.(7);Zhou, Q.(7);Xuan, S.(7);Louis, E.(8);
(1)University College Cork, College of Medicine and Health, Cork, Ireland;(2)Western University, n/a, London, Canada;(3)University of São Paulo, Ribeirão Preto Medical School, São Paulo, Brazil;(4)Centro Hospitalar e Universitário São João, n/a, Porto, Portugal;(5)Mount Sinai Hospital, IBD Clincal Center, New York, United States;(6)Tohoku University Graduate School of Medicine, Division of Gastroenterology, Sendai, Japan;(7)AbbVie Inc., n/a, Chicago, United States;(8)Centre Hospitalier Universitaire de Liège, Department of Gastroenterology, Liège, Belgium;
P435: Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS studyECCO’23 CopenhagenYear: 2023
Authors: Buisson, A.(1)*;Jammet, A.(1);Pereira, B.(2);Fumery, M.(3);
(1)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrand, France;(2)CHU Clermont-Ferrand, Biostatistics Unit, Clermont-Ferrand, France;(3)CHU Amiens, IBD Unit, Amiens, France;
P436: Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn's disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trialECCO’23 CopenhagenYear: 2023
Authors: Schreiber, S.W.(1)*;Lee, S.(2);van der Woude , C.J.(3);Marín-Jiménez , I.(4);Wolf, D.(5);Schnoy, E.(6);Salzberg , B.(7);Busse , C.(8);Nazar, M.(9);Langholff, W.(10);Borghorst, S.(11);Gasink, C.(8);Baker, T.(12);Godwin, B.(8);Feagan, B.(13);
(1)Christian-Albrechts-University and University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(2)University of Washington, Division of Gastroenterology, Seattle, United States;(3)Erasmus University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(4)Hospital Universitario Gregorio Marañón- IiSGM, Gastroenterology Unit, Madrid, Spain;(5)Atlanta Gastroenterology Associates, Center for Crohn's Disease & Ulcerative Colitis, Atlanta, United States;(6)University Hospital of Augsburg, Internal Medicine III- Gastroenterology, Augsburg, Germany;(7)IBD Center of Atlanta, Atlanta Gastroenterology Specialists PC, Atlanta, United States;(8)Janssen Scientific Affairs- LLC, Gastroenterology, Horsham, United States;(9)Janssen-Cilag Polska Sp. z.o.o., Gastroenterology, Warsaw, Poland;(10)Janssen Research & Development- LLC, Biostatistics, Spring House, United States;(11)Janssen-Cilag GMBH, Health Economics/Market Access/Reimbursement, Neuss, Germany;(12)Janssen Research & Development- LLC, Immunology, Spring House, United States;(13)University of Western Ontario, Division of Gastroenterology- Department of Medicine, London, Canada;POWER Investigators
P437: Early therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome .ECCO’23 CopenhagenYear: 2023
Authors: Carrillo Palau, M.(1)*;Alonso-Abreu, I.(1);Morant, A.(1);Vera, B.(1);Vela , M.(2);Ramos, L.(1);Franco, A.(3);Reygosa, C.(1);Barrios, Y.(3);Medina Chico, J.S.(1);Globio, V.(4);Hernández-Perez, A.(1);Jiménez, A.(5);Hernández-Guerra, M.(1);
(1)Hospital Universitario De Canarias, Gastroenterology, Santa Cruz De Tenerife, Spain;(2)Hospital Universitario Nuestra Señora de La Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(3)Hospital Universitario de Canarias, Immunology, Santa Cruz de Tenerife, Spain;(4)La Laguna University, Medicine Faculty, Santa Cruz de Tenerife, Spain;(5)Hospital Universitario de Canarias, Research, Santa Cruz de Tenerife, Spain;
P438: Efficacy and safety of ustekinumab for Ulcerative Colitis through 4 years in Asian patients: Final results from the sub-population of UNIFI long-term extensionECCO’23 CopenhagenYear: 2023
Authors: Hisamatsu, T.(1)*;Kim, H.J.(2);Motoya, S.(3);Suzuki, Y.(4);Ohnishi, Y.(5);Marano, C.(6);Imai, Y.(7);Saadoun, C.(8);Zhuo, J.(9);Kawamura, S.(8);
(1)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(2)Kyung Hee University College of Medicine, Center for Crohn's and Colitis- Department of Gastroenterology, Seoul, Korea- Republic Of;(3)Sapporo-Kosei General Hospital, IBD Center- Hokkaido Prefectural Welfare Federation of Agricultural Cooperative, Hokkaido, Japan;(4)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine-, Sakura, Japan;(5)Shizuoka Medical Center, Division of Gastroenterology, Shizuoka, Japan;(6)Janssen Research & Development- LLC, Immunology, Spring House, United States;(7)Janssen Pharmaceuticals K.K. Japan, Immunology, Tokyo, Japan;(8)Janssen Pharmaceuticals Asia Pacific, Immunology, Singapore, Singapore;(9)Janssen China Research & Development, Biostatistics, Shanghai, China;UNIFI Investigators
P439: Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Panés, J.(1)*;Louis, E.(2);Bossuyt, P.(3);Joshi, N.(4);Lee, W.J.(4);Lacerda, A.(4);Remple, V.(4);Xuan, S.(4);Loftus Jr. , E.V.(5);
(1)Hospital Clinic Barcelona- IDIPABS- CIBERehd, n/a, Barcelona, Spain;(2)University Hospital CHU of Liège, n/a, Liège, Belgium;(3)Imelda General Hospital, n/a, Bonheiden, Belgium;(4)AbbVie Inc., n/a, Chicago, United States;(5)Mayo Clinic College of Medicine and Science, n/a, Rochester, United States;
P440: Prevalence of NUDT15 polymorphisms and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease patients: A systematic review and meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Yu, N.(1);Sriranganathan, D.(2);Walker, G.J.(3);Sazonovs, A.(4);Wilding, H.(5);Kennedy, N.A.(6,7);Ahmad, T.(6,7);Boyapati, R.K.(8,9);Segal, J.P.(10,11);Ding, N.J.S.(1,11)*;
(1)St Vincent's Hospital Melbourne, Gastroenterology, Melbourne, Australia;(2)Whipps Cross University Hospital, Gastroenterology, London, United Kingdom;(3)Torbay and South Devon NHS Foundation Trust, Gastroenterology, Torquay, United Kingdom;(4)Wellcome Sanger Institute, Genomics of Inflammation and Immunity Group, Hinxton, United Kingdom;(5)St Vincent's Hospital Melbourne, Library Service, Melbourne, Australia;(6)Royal Devon and Exeter Hospital NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(7)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(8)Monash Health, Gastroenterology, Melbourne, Australia;(9)Monash University, Medicine, Melbourne, Australia;(10)Northern Hospital, Gastroenterology, Melbourne, Australia;(11)The University of Melbourne, Medicine, Melbourne, Australia;
P441: Long-term CD treatment failure and dose modification rates with vedolizumab and other biologics: Results from a large prospective observational studyECCO’23 CopenhagenYear: 2023
Authors: Siegmund, B.(1)*;Siegel, C.A.(2);Sebastian, S.(3);Zhou, J.(4);Jones, S.(5);Adsul, S.(4);Louis, E.(6);
(1)Charité – Universitätsmedizin Berlin- Campus Benjamin Franklin, Medical Department- Division of Gastroenterology- Infectiology and Rheumatology-, Berlin, Germany;(2)Dartmouth Hitchcock Medical Center, Gastroenterology and Hepatology, Lebanon- NH, United States;(3)Hull University Teaching Hospital, IBD Unit, Hull, United Kingdom;(4)Takeda, Gastroenterology, Cambridge- MA, United States;(5)Takeda, Gastroenterology, Zurich, Switzerland;(6)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;
P442: Endoscopic resection of visible precancerous lesions in patients with colonic Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Busacca, A.(1)*;De Sire, R.(1);Capogreco, A.(1);Dal Buono, A.(2);Gabbiadini, R.(2);Loy, L.(2);Finati, E.(1);Spadaccini, M.(1);Maselli, R.(1);Hassan, C.(1);Repici, A.(1);Armuzzi, A.(2);
(1)IRCCS Humanitas Research Hospital, Endoscopy Unit- Department of Gastroenterology, Rozzano, Italy;(2)IRCCS Humanitas Research Hospital, IBD Unit- Department of Gastroenterology, Rozzano, Italy;
P443: Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort StudyECCO’23 CopenhagenYear: 2023
Authors: Le Cosquer, G.(1);Gilletta, C.(1);Amiot, A.(2);Rivière, P.(3);Nachury, M.(4);Rouillon, C.(5);Bouhnik, Y.(6);Abitbol, V.(7);Nancey, S.(8);Fumery, M.(9);Savoye, G.(10);Biron , A.(11);Picon, L.(12);Peyrin-Biroulet, L.(13);Vidon, M.(14);Reenaers, C.(15);Simon, M.(16);Caron, B.(13);Serrero , M.(17);Altwegg, R.(18);Benezech, A.(19);Goutorbe, F.(20);Rahier, J.F.(21);Beaugerie, L.(22);Pelletier, A.L.(23);Caillo, L.(24);Laharie, D.(3)*;Poullenot, F.(3);
(1)Toulouse Rangueil University Hospital, Department of Gastroenterology and Pancreatology, Toulouse, France;(2)Hôpital Bicêtre, Department of Gastroenterology, Le Kremlin Bicêtre, France;(3)CHU de Bordeaux, Service d'Hépato-gastroentérologie et oncologie digestive, Bordeaux, France;(4)Lille University Hospital, Department of Gastroenterology and Hepatology, Lille, France;(5)Caen University Hospital, Hepato-gastroenterology Department, Caen, France;(6)Beaujon Hospital, Department of Gastroenterology, Clichy, France;(7)Hôpital Cochin, Department of Gastroenterology, Paris, France;(8)Lyon University Hospital, Department of Gastroenterology, Lyon, France;(9)Amiens University Hospital, Department of Gastroenterology, Amiens, France;(10)Rouen University Hospital-Charles Nicolle, Department of Gastroenterology, Rouen, France;(11)Reims University Hospital, Department of Gastroenterology, Reims, France;(12)Tours University Hospital, Department of Gastroenterology, Tours, France;(13)Nancy University Hospital, Department of Gastroenterology, Nancy, France;(14)Hôpital Intercommunal de Créteil, Department of Gastroenterology, Créteil, France;(15)CHU Sart Tilman, Department of Gastroenterology, Liège, Belgium;(16)Institut Mutualiste Montsouris, Department of Gastroenterology, Paris, France;(17)APHM Hôpital Nord, Department of Gastroenterology, Marseille, France;(18)Saint-Eloi Hospital, Department of Gastroenterology, Montpellier, France;(19)Henri Duffaut Hospital, Department of Gastroenterology, Avignon, France;(20)Cote Basque Hospital, Department of Gastroenterology and Hepatology, Bayonne, France;(21)Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Department of Gastroenterology, Yvoir, Belgium;(22)Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France;(23)Bichat Hospital, Department of Gastroenterology, Paris, France;(24)Nimes University Hospital, Department of Gastroenterology, Nimes, France;
P444: A systematic literature review (SLR) of real-world studies of advanced therapies in moderate-to-severe ulcerative colitis (UC): study, patient and clinical characteristics, and outcomes assessedECCO’23 CopenhagenYear: 2023
Authors: Irving, P.M.(1);Hur, P.(2)*;Gautam, R.(3);Guo, X.(4);Vermeire, S.(5);
(1)Guy's and St Thomas' Hospital- Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(2)Pfizer Inc, HEOR - Inflammation and Immunology, New York, United States;(3)EVERSANA Pvt. Ltd., HEOR/Real-World Evidence, Mumbai, India;(4)Pfizer Inc, Gastroenterology- Inflammation and Immunology, Collegeville- PA, United States;(5)University Hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;
P445: Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn's Disease and Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Peyrin-Biroulet, L.(1);Bossuyt, P.(2);Bettenworth, D.(3);Loftus Jr., E.V.(4);Anjie, S.(5);D'Haens, G.(5);Saruta, M.(6);Arkkila, P.(7);Kim, D.H.(8);Choi, D.(8);Reinisch, W.(9)*;
(1)Centre Hospitalier Régional Universitaire de Nancy, Department of Gastroenterology, Nancy, France;(2)Imelda GI Clinical Research Centre, Imelda General Hospital, Bonheiden, Belgium;(3)University of Münster, Medical Faculty, Münster, Germany;(4)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;(5)Amsterdam UMC University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)The Jikei University School of Medicine, Department of Internal Medicine, Tokyo, Japan;(7)Helsinki University Hospital, Department of Gastroenterology, Helsinki, Finland;(8)Celltrion Healthcare Co., Ltd, Incheon, Korea- Republic Of;(9)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria;
P446: The INTESTINE study: INtended TEmporary STomas In crohN's diseasEECCO’23 CopenhagenYear: 2023
Authors: Perrott, C.(1)*;Calini, G.(2);Gori, A.(3);Rottoli, M.(3);Garoufalia, Z.(4);Wexner, S.(4);Celentano, V.(1);
(1)Chelsea & Westminster Hospital, General Surgery, London, United Kingdom;(2)University of Udine, General Surgery, Udine, Italy;(3)Alma Mater Studiorum University of Bologna, Department of Medical and Surgical Sciences, Bologna, Italy;(4)Cleveland Clinic Florida, Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Weston, United States;The INTESTINE Study Group
P447: Early predictors of the need for surgery in patients with acute severe ulcerative colitis: results of the prospective, observational, international ESCP MASC studyECCO’23 CopenhagenYear: 2023
Authors: Frasson, M.(1);Pinkney, T.(2);Gisbert, J.P.(3);Rodriguez-Lago, I.(4);Blackwell, S.(5);Gecse, K.B.(6);Buskens , C.J.(7);Knowles, C.(8);Zmora, O.(9);Brookes, M.(10);Fiorino, G.(11);Nos, P.(12);Gallo, G.(13);Pata, F.(14);Verjee, A.(15);Leone, S.(16);PellinoMD- PhD- FRCS- FEBS Colo- FASCRS- FACS, G.(17)*;
(1)Hospital La Fe Valencia, Colorectal Surgery, Valencia, Spain;(2)Queen Elizabeth Hospital- University of Birmingham, Academic Department of Surgery, Birmingham, United Kingdom;(3)- Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid UAM, Gastroenterology Unit, Madrid, Spain;(4)Hospital Universitario de Galdakao- Biocruces Bizkaia Health Research Institute, Gastroenterology Department, Galdakao, Spain;(5)Patient representative, Patient representative, Liverpool, United Kingdom;(6)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)Amsterdam UMC, Department of Surgery, Amsterdam, The Netherlands;(8)Queen Mary University of London, Blizard Institute Knowles- Centre for Neuroscience- Surgery & Trauma, London, United Kingdom;(9)Assaf Harofeh Medical Center, Division of General Surger, Zerifin, Israel;(10)Royal Wolverhampton NHS Trust, Department of Gastroenterology, Wolverhampton, United Kingdom;(11)IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Department of Gastroenterology and Digestive Endoscopy, Milan, Italy;(12)La Fe University Hospital, Department of Gastroenterology, Valencia, Spain;(13)Sapienza University of Rome, Department of Surgical Sciences-, Rome, Italy;(14)Nicola Giannettasio Hospital, General Surgery Unit, Corigliano-Rossano, Italy;(15)Patient representative, Patient representative, London, United Kingdom;(16)AMICI Italia Onlus, Patient representative, Milan, Italy;(17)Università degli Studi della Campania "Luigi Vanvitelli", Department of Advanced Medical and Surgical Sciences, Naples, Italy;on behalf of the MASC Study Collaborators
P448: Long term effectiveness of first-line infliximab treatment compared to conventional treatment in paediatric moderate-to-severe Crohn's disease – an update from the TISKids studyECCO’23 CopenhagenYear: 2023
Authors: Vuijk, S.(1)*;Jongsma, M.(1);Cozijnsen, M.(1);van Pieterson, M.(1);de Meij, T.(2);Norbruis, O.(3);Groeneweg, M.(4);Wolters, V.(5);van Wering, H.(6);Hojsak, I.(7);Kolho, K.L.(8);Hummel, T.(9);Stapelbroek, J.(10);van der Feen, C.(11);van Rheenen, P.(12);van Wijk, M.(2);Teklenburg, S.(3);Escher, J.(1);de Ridder, L.(1);
(1)Erasmus Medical Center / Sophia Children's Hospital, Department of Paediatric Gastroenterology, Rotterdam, The Netherlands;(2)Emma Children's Hospital- Amsterdam UMC- VU University, Department of Paediatric Gastroenterology, Amsterdam, The Netherlands;(3)Isala Hospital, Department of Paediatric Gastroenterology, Zwolle, The Netherlands;(4)Maasstad Hospital, Department of Paediatric Gastroenterology, Rotterdam, The Netherlands;(5)Utrecht Medical Center/ Wilhelmina Children's Hospital, Department of Paediatric Gastroenterology, Utrecht, The Netherlands;(6)Amphia Hospital, Department of Paediatric Gastroenterology, Breda, The Netherlands;(7)Children's Hospital Zagreb, Department of Paediatric Gastroenterology, Zagreb, Croatia;(8)University of Helsinki, Department of Pediatric Gastroenterology, Helsinki, Finland;(9)Medical Spectrum Twente, Department of Paediatric Gastroenterology, Enschede, The Netherlands;(10)Catharina Hospital, Department of Paediatric Gastroenterology, Eindhoven, The Netherlands;(11)Jeroen Bosch Hospital, Department of Paediatric Gastroenterology, ‘s Hertogenbosch, The Netherlands;(12)University of Groningen- University Medical Center, Department of Paediatric Gastroenterology, Groningen, The Netherlands;
P450: Real life Effectiveness and safety of an induction treatment with tofacitinib in patients with Ulcerative Colitis: First results of the French TOFAST cohortECCO’23 CopenhagenYear: 2023
Authors: Fumery, M.(1)*;Bouhnik, Y.(2);Faure, P.(3);Bouzidi, A.(4);Brault, Y.(5);Peyrin-Biroulet, L.(6);Laharie, D.(7);
(1)CHU Amiens, Gastroenterology and Hepatology, Amiens, France;(2)Groupe hospitalier Ambroise Paré - Hartmann, Institut des MICI, Neuilly sur Seine, France;(3)Clinique Pasteur, Hepatology and gastroenterology, Tououse, France;(4)Pfizer, Infammation & Immunology, Paris, France;(5)Pfizer, Inflammation & Immunology, Paris, France;(6)University Hospital, Gastroenterology, Nancy, France;(7)Hepatology and Gastroenterology, CHU Bordeaux, Bordeaux, France;
P451: Early infliximab trough levels in paediatric IBD patients predict sustained remissionECCO’23 CopenhagenYear: 2023
Authors: BeversMD, N.(1)*;Aliu, A.(2);Wong, D.(3);Derijks, L.(4);Winkens, B.(5);Vreugdenhil, A.(6);Pierik, M.(7);van Rheenen, P.(8);
(1)Zuyderland Medical Centre, Department of Paediatrics, Heerlen, The Netherlands;(2)Maastricht University, Department of internal medicine- division of Gastroenterology and Hepatology- School for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;(3)Zuyderland Medical Center, Department of Clinical pharmacy- Pharmacology and Toxicology, Sittard, The Netherlands;(4)Maxima Medical Centre, Department of Clinical pharmacy, Veldhoven, The Netherlands;(5)Maastricht University, Department of Methodology and Statistics- Care and Public Health Research Institute CAPHRI, Maastricht, The Netherlands;(6)Maastricht University Medical Centre, Department of Paediatrics and NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands;(7)Maastricht University Medical Center, Department of Internal Medicine- Division of Gastro-enterology and Hepatology-School for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;(8)University of Groningen- University Medical Centre Groningen - Beatrix Children's Hospital, Department of Paediatric Gastroenterology Hepatology and Nutrition, Groningen, The Netherlands;
P452: Fecal Microbiota Transplantation Leads to Lower IBD Related Complications in Hospitalized Inflammatory Bowel Disease Patients with Clostridioides difficile Infection: A retrospective cohort studyECCO’23 CopenhagenYear: 2023
Authors: Le, P.H.(1)*;Chiu, C.H.(2);Chiu, C.T.(1);Kuo, C.J.(1);Yeh, P.J.(3);Chen, C.C.(3);Pan, Y.B.(4);
(1)Chang Gung Memorial Hospital- Linkou Branch, Department of Gastroenterology and Hepatology, Taoyuan, Taiwan;(2)Chang Gung Memorial Hospital, Chang Gung Microbiota Therapy Center, Taoyuan, Taiwan;(3)Chang Gung Memorial Hospital- Linkou Branch, Department of Pediatric Gastroenterology, Taoyuan, Taiwan;(4)Chang Gung Memorial Hospital- Linkou Branch, Biostatistical Section- Clinical Trial Center, Taoyuan, Taiwan;
